[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350599-105":59,"doc-detail-350599-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-role-of-mirna-32-in-non-small-cell-lung-cancer","The role of miRNA-32 in non-small cell lung cancer","","This clinical trial and experimental study evaluates whether miRNA-32 influences non-small cell lung cancer (NSCLC) cell proliferation and migration by regulating myocyte enhancer factor 2D (MEF2D). Quantitative real-time PCR measures miRNA-32 in NSCLC tissues and cell lines, while Western blotting assesses MEF2D and pathway-related proteins, with Cell Counting Kit-8 and Transwell assays for function. A dual-luciferase assay confirms direct targeting of MEF2D by miRNA-32, and MEF2D overexpression reverses miRNA-32–mediated suppression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-role-of-mirna-32-in-non-small-cell-lung-cancer/350599/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-role-of-mirna-32-in-non-small-cell-lung-cancer/350599.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main objective regarding miRNA-32 in NSCLC?","Question",{"text":112,"@type":113},"To determine whether miRNA-32 affects NSCLC cell proliferation and migration by regulating MEF2D expression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was miRNA-32 expression measured in the study?",{"text":117,"@type":113},"Quantitative real-time PCR was used to evaluate miRNA-32 levels in clinical NSCLC tissue specimens and cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links miRNA-32 to MEF2D and NSCLC behavior?",{"text":121,"@type":113},"miRNA-32 directly binds to the MEF2D 3’UTR, inhibiting MEF2D translation; overexpressing MEF2D reverses miRNA-32’s inhibitory effects.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350599,1791173347,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","®  \n Clinical Trial/Experimental Study   \nThe role of miRNA-32 in non-small cell lung cancer  \nDongxiao Ding, MSca , Haihua Hong, MScb , Ke Shi, MSca ,*  \n\n| Abstract\u003Cbr>Background: This study aimed to investigate whether miRNA-32 affects the proliferation and migration of non-small cell lung cancer (NSCLC) cells by regulating the expression of myocyte enhancer factor 2D (MEF2D) .\u003Cbr>Methods: Quantitative real-time polymerase chain reaction was utilized to evaluate the expression levels of miRNA-32 in clinical NSCLC tissue specimens and cell lines. Western blotting was employed to detect the protein expression levels of MEF2D, E-cadherin, N-cadherin, and CyclinD1, as well as to verify transfection efficiency. Cell proliferation and migration were assessed using Cell Counting Kit-8 and Transwell assays, respectively. Additionally, a dual-luciferase reporter gene assay was performed to validate the targeted regulatory relationship between miRNA-32 and MEF2D.\u003Cbr>Results: miRNA-32 was significantly downregulated in lung cancer tissues and cell lines, whereas MEF2D exhibited significant upregulation. High miRNA-32 expression correlated with poor clinical outcomes in NSCLC across both our in-house cohort and the TCGA cohort. The stable overexpression of miRNA-32 in lung cancer cells markedly inhibited their proliferation and migratory capabilities. Mechanistically, miRNA-32 inhibited the translation of MEF2D by directly binding to its 3’UTR region. Crucially, the overexpression of MEF2D significantly reversed the inhibitory effects of miRNA-32 on lung cancer cell proliferation and migration. Conclusion: The miRNA-32/MEF2D signaling axis plays a pivotal role in the proliferation and metastasis of NSCLC, highlighting its potential as a diagnostic biomarker and prognostic indicator for the disease.\u003Cbr>Abbreviations: CCK-8 = Cell Counting Kit-8, DDP = diamminedichloroplatinum, LUAD = lung adenocarcinoma, MEF2D = Myocyte enhancer factor 2D, NSCLC = Non-small cell lung cancer. |\n| --- |\n| Keywords: MEF2D, migration, miRNA-32 , non-small cell lung cancer, proliferation |\n\n1. Introduction  \nLung cancer remains one of the leading causes of cancer-related mortality globally.[1] The incidence is notably higher in industrialized and transitional nations, driven by major risk factors such as smoking, asbestos exposure, and air pollution. [2] The majority of patients present with metastasis at the time of diagnosis, resulting in a 5-year survival rate of \u003C20% . [3] Non-small cell lung cancer (NSCLC) accounts for approximately 80% to 85% of all lung cancer cases. [4] Although targeted therapies and conventional chemotherapy remain standard treatment modalities, overall survival rates have not seen dramatic improvements. The advent of immunotherapy has significantly enhanced patient prognoses and altered the treatment landscape for lung cancer, yielding survival rates up to 5 times higher than those achieved with chemotherapy alone. [5,6] Nevertheless, only a subset of patients derive long-term benefits, with the majority experiencing non-response or disease progression during treatment.  \nTherefore, identifying reliable predictive and prognostic biomarkers remains a critical imperative in the clinical management of lung cancer.  \nMyocyte enhancer factor 2D (MEF2D), a member of the MEF2 (MADS-box transcription factor) family, functions asa transcription factor regulating growth, development, and signal transduction. [7] While earlier studies primarily linked MEF2D to muscular and nervous system development, recent evidence underscores its involvement in tumorigenesis. [8,9] For instance, MEF2D is highly expressed in gastric cancer, where it correlates with a poor prognosis. [10] Furthermore, Ling et al[11] demonstrated that MEF2D knockdown inhibits β-catenin translocation within the Wnt pathway, thereby suppressing the proliferation and invasion of NSCLC cells. Multiple studies have also indicated that MEF2D is targeted and regulated by various miR","cbCaiq6tUTtbsurf","https://ap.wps.com/l/cbCaiq6tUTtbsurf","pdf",3557542,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is the study’s main objective regarding miRNA-32 in NSCLC?\",\"answer\":\"To determine whether miRNA-32 affects NSCLC cell proliferation and migration by regulating MEF2D expression.\"},{\"question\":\"How was miRNA-32 expression measured in the study?\",\"answer\":\"Quantitative real-time PCR was used to evaluate miRNA-32 levels in clinical NSCLC tissue specimens and cell lines.\"},{\"question\":\"What mechanism links miRNA-32 to MEF2D and NSCLC behavior?\",\"answer\":\"miRNA-32 directly binds to the MEF2D 3’UTR, inhibiting MEF2D translation; overexpressing MEF2D reverses miRNA-32’s inhibitory effects.\"}]","The role of miRNA-32 in non-small cell lung cancer | PDF",1790089834,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee6c7845f8d62763e3025d44d98e1cd2.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a4dc90ae91c1ddd4d490de36bb2d37b.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9595f26e18c9e5a4ee8a1d7bd2655005.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2161a2f973249319890f325583638938.webp",980,1306]